Adaptimmune CEO Adrian Rawcliffe at EUBIO22 (Rachel Kiki for Endpoints News)

March 6, 2023 07:19 AM EST

Months after reorg, Adaptimmune merges with fellow cell therapy developer

Amber Tong

Adaptimmune is merging with TCR² Therapeutics in a bid to create a T cell therapy developer aimed at solid tumors.

The

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Lilly makes a move for long-acting incretins in tech deal with Swedish biotech

Pharma companies rush in to buy what they hope will rival Keytruda

At ASCO, cell therapies for deadly form of brain cancer make early strides

Remote patient monitoring is ready for its moment

Agenus quickly exits CDMO business by selling assets to Zydus for $75M upfront

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...